Partnering - Confo Therapeutics

Catalyzing breakthroughs, together with partners.

In our partnerships, we collaborate with a common goal in mind: to meaningfully improve the lives of patients

Discuss the opportunities

Introduction
Innovating together

Partner up?

Get in contact

We are open to partnership opportunities that strategically align with both our own goals and those of prospective partners. We partner with global pharmaceutical companies to maximize the positive potential impact of our product candidates.

We forge early-stage partnerships to solve tough challenges on GPCR targets of high therapeutic interest. We can break new ground and develop novel therapies by broadly applying our technology to generate novel small molecules and antibody-based therapeutics with desirable product profiles, fulfilling the goals of our partners.

Industry leaders trust Confo Therapeutics

Our partnerships over the years with top-tier pharmaceutical companies and investors underscore our credibility and leadership in the GPCR drug discovery space

“Partnerships are fundamental to our business strategy and leverage our technology to accelerate innovation and expand its impact” Stephen Dowd | Chief Business Officer

"Innovation is at the heart of our mission. Our GPCR platform technology is driving the development of groundbreaking therapies" Christel Menet | Chief Scientific Officer

“Collaboration and innovation are key to our success. We strive to expand the reach and impact of our technology through strategic alliances and partnerships” Franky Van Herreweghe | Business Development Manager

"We leverage our cutting-edge platform technology to accelerate the discovery and development of novel treatments in partnership with leading pharmaceutical companies” Joan Vermeiren | Head of Development Project Management

Partnerships

Innovating together for a greater impact

We work closely with our partners, leveraging our expertise in GPCR-targeted drug discovery and development to push the boundaries of what’s possible. By combining our strengths and sharing insights, we create a powerful synergy that accelerates the development of novel therapies. Whether with a global pharmaceutical player or an emerging biotech, our partnerships are designed to be collaborative, and focused on achieving results. Our collaborations over the years with Eli Lilly, Roche, Daiichi Sankyo, Lundbeck, Regeneron and AbCellera highlight our credibility in GPCR drug discovery.

Collaboration

Our partnership with Lilly

We have a worldwide licensing agreement with Eli Lilly and Company.   This centers on the clinical stage candidate, CFTX-1554, a novel inhibitor of the angiotensin II type 2 receptor (AT2R). The molecule is being developed as a non-opioid approach to treating neuropathic pain. The partnership also considers an additional program to further develop Confo’s existing therapeutic antibody candidates targeting the same receptor. Existing pain therapies often fall short of effectively reducing symptoms and carry risks of serious side effects and addiction. Patients living with chronic pain remain in urgent need of novel analgesics that are efficacious and well-tolerated and can improve quality of life. This program greatly benefits from Lilly’s experience and global organization.

Let’s shape the future of GPCR-directed therapies together

As we advance our science and expand our pipeline, we continue to grow our portfolio of strategic collaborations with key industry partners. We invite you to reach out and explore how partnering with Confo Therapeutics can unlock new opportunities and drive mutual success. Get in touch to discuss how we can work together to bring innovative therapies to life.

Questions?

e-mail: [email protected]
tel. +32 9 396 74 00

"*" indicates required fields